PSTX News and Press, Poseida Therapeutics Inc. From 11/10/22

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 PR Newswire Entered into a strategic collaboration with Roche to develop allogeneic CAR-T cell therapies for hematological indications; received $110 million upfront payment a...

Poseida Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering p...

Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress PR Newswire SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engin...

Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition PR Ne...

If you’re looking for the best penny stocks to buy, you likely understand the disconnect between broader trends and cheap stocks. Since penny stocks move independently, most of the time, you’re sure to find at least a few companies to follow. Today this became more evi...

Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting PR Newswire SAN DIEGO , Oct. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-s...

Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing propriet...

Summary Poseida announced a collaboration agreement on Aug.3 focused on allogeneic CAR-T Program in hematologic cancers with Roche, potentially worth $6 billion; $110 million upfront, $110 million in near-term milestones; other collaboration benefits. This is Poseida's second majo...

The following slide deck was published by Poseida Therapeutics, Inc. in conjunction with this event. For further details see: Poseida Therapeutics (PSTX) Investor Presentation - Slideshow

Poseida Therapeutics press release ( NASDAQ: PSTX ): Q2 GAAP EPS of -$0.69 beats by $0.08 . Revenue of $2.7M beats by $1.77M . For further details see: Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M